🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06570122
Recruiting Not applicable

Mobile Phone-Based Smoking-Cessation Intervention for Smoking Parents

NCT06570122 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Normal University
Phase
Not applicable
Started
2025-09-01
Last updated
2026-09-02

Condition(s) studied

Smoking Cessation

Investigational drug(s) / intervention(s)

5A's/5R's adviceHealth warning leafletAI-powered chatbot support

5A's/5R's advice: 5A's (Ask, Advise, Assess, Assist, Arrange) for smokers who are ready to quit, and 5R's (relevance, risks, rewards, roadblocks, and repetition) for smokers who are not ready to quit.

Health warning leaflet: The health warning leaflet provides essential information on the dangers of secondhand and thirdhand smoke. It outlines how exposure to these forms of smoke can harm both smokers and non-smokers, particularly children, by increasing the risk of respiratory illnesses and other health issues.

AI-powered chatbot support: Participants will receive three months of AI-powered chatbot, equipped with personalized interactions and real-time support, via WeChat.

Study summary

This study aims to explore the feasibility and preliminary effectiveness of a mobile phone-based intervention tailored specifically for smoking parents.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
Accepted
Inclusion Criteria: 1. aged 18 and above, reside in Zhuhai for the next 6 months 2. smoke at least 1 cigarette or use e-cigarettes daily 3. have a smartphone and a WeChat account, able to use WeChat skillfully Exclusion Criteria: 1. Smokers who have communication barrier (either physically or cognitively) 2. Smokers who are currently participating in other SC programmes or services

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Beijing Normal University Zhuhai Guangdong Recruiting

More Beijing Normal University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06570122 on ClinicalTrials.gov ↗ ← All trials in China